

33. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol.* 2018; 6(5):361-369.)
34. Landgraf W, Owens DR, Frier BM, Zhang M, Bolli GB. Fasting C peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. *Diabetes Obes Metab.* 2019;22:315-323.)
35. Rosenstock J, Nino A, Soffer J, et al. Impact of a weekly glucagon like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. *Diabetes Care.* 2020;43(10):2509-2518.
36. Bolli GB, Porcellati F, Meier JJ. Switching from insulin bolus treatment to GLP-1 RAs added to continued basal insulin in people with type 2 diabetes on basal-bolus insulin. *Diabetes Care.* 2020;43(10): 2333-2335)
37. Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2021;44(11):2589-2625.
38. Jacobsen LM, Bocchino L, Evans-Molina C, et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. *Diabetologia.* 2020;63(3):588-596.